bioRxivImmunology
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
A. C. Walls, L. A. VanBlargan, K. Wu, A. Choi, M. J. Navarro, D. Lee, L. Avena, D. M. Berrueta, M. N. Pham, S. Elbashir, M. C. Miranda, E. Kepl, M. Johnson, A. Blackstone, K. R. Sprouse, B. Fiala, M. A. O'Connor, N. Brunette, P. S Arunachalam, L. Shirreff, K. A. Rogers, L. Carter, D. H. Fuller, F. J. Villinger, B. Pulendran, , D. Veesler
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOC) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOC. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses against VOC, as compared to non-human primates or humans, suggesting caution should be exercised when interpreting data for this animal model.
- organism: human
- organism: mouse
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2
F. Amanat, S. Strohmeier, … F. Krammer·bioRxiv·Aug 5, 2021
- Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
L. Wang, M. H. Kainulainen, … Davis·bioRxiv·Nov 24, 2021
- Evaluation of the cross reactivity of neutralising antibody response in vaccinated human and convalescent hamster sera against SARS-CoV-2 variants up to and including JN.1 using an authentic virus neutralisation assay
N. S. Coombes, K. R. Bewley, … S. G. P. Funnell·bioRxiv·Oct 21, 2023
- Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccination
K. Ng, N. Faulkner, … G. Kassiotis·bioRxiv·Nov 30, 2021
- Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
W.-t. He, M. Yuan, … R. Andrabi·bioRxiv·Jul 5, 2021
- Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
K. Wu, A. Choi, … D. K. Edwards·bioRxiv·Apr 13, 2021